/ /

  • linkedin
  • Increase Font
  • Sharebar

    How new eye drop is stabilizing and relieving dry eye

    Water-free treatment has 'very positive' outlook for patients

    Take-home message: A new lubricant eye drop that specifically targets tear film evaporation in dry eye disease seems safe and effective for treating mild to moderate evaporative disease.

    Cologne, Germany—A novel lubricant eye drop that specifically targets tear film evaporation seems to be safe and effective in treating mild-to-moderate hyperevaporative dry eye disease.

    The product, perfluorohexyloctane, or F6H8 (NovaTears, Novaliq), improved four of five parameters studied, especially the Ocular Surface Disease Index (OSDI). The non-preserved formulation is from the family of semifluorinated alkanes and has been approved by the European Medical Device Directive as a medical device with a nonblurring wetting agent for the ocular surface.

    Related: What clinicians should know about ocular allergies

    “F6H8 represents a groundbreaking water-free concept for treatment of evaporative dry-eye disease through outstanding spreading properties and eligible biocompatibility,” said Philipp Steven, MD, principle investigator of the Ocular Surface Group, Department of Ophthalmology, and director of the Ocular GvHD Competence Center, University of Cologne, Cologne, Germany.

    Dr. Steven and his team conducted a prospective, two-center, observational 6-week study of 30 patients from two dry eye outpatient clinics—the University of Cologne and the Augenarztpraxis Heidelberg—who were instructed to instill one drop of F6H8 four times a day in both eyes.

    Related dry eye: When old, new technologies converge for dry eye diagnosis

    The objective of the study was to determine if the formulation could stabilize the tear film and relieve symptoms of dry eye. Investigators evaluated the effect of F6H8 on best-corrected visual acuity (BCVA), IOP, Schirmer I test results, tear fluid osmolarity, tear film break-up time (TFBUT), corneal staining, meibum secretion, and the OSDI. Patients were asked to complete a questionnaire at the end of the study to measure the product usability and patient satisfaction, Dr. Steven noted.


    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results